FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966072279> ?p ?o ?g. }

• W2966072279 abstract "18614 Background: Primary adrenocortical carcinoma (PAC) is a rare disease with a incidence of 1 per million. PAC’s are highly malignant tumors with guarded prognosis. Radical surgery is the treatment of choice. Methods: The pathology database and medical charts of these patients were retrospectively reviewed. Results: There were 14 females, 8 males, and 95% were caucasion. The mean age was 49.2 ± 11.8 years (females 51.6 years, males 45 years). The mean size of the tumor was 12.6 ± 5.1 cm (range of 3.6 to 25 cm). Thirteen patients (59.1%) presented with left and nine (40.9%) with right sided PAC. Seventy- two percent of the patients had abdominal, back, and/or flank pain. Forty five percent of patients had symptoms related to hypercortisolism and/or hyperandrogenism. Twelve patients (55%) had functional tumors (hypercortisolism 67%, hyperandrogenism 42%, and DHEA-S hypersecretion 42%) and ten were non-functional. Five percent of the tumors were classified as stage I, 33% were stage II, 38% were stage III, and 24% were stage IV. Twelve patients (55%) had distant metastases (liver 75%, lung 67%, retroperitoneum 33%, kidney 17%, contra-lateral adrenal gland 17%). All 22 patients had adrenalectomies (open 91%; laparoscopic 9%). The microscopic margin of resection were negative in 14 and positive in 6 patients. The information for 18 patients were evaluable for treatment. Eight patients received post-op therapy. Four patients received Mitotane (o,p’-DDD) alone (three died at 2, 29, and 213 months; and one is alive at 38 months after diagnosis). Three patients received both Mitotane and chemotherapy (two died at 3 and 43 months, one is alive at 140 months). One patient received only chemotherapy and died at 8 months. Ten patients received no post-op therapy. The estimated 5-year survival for the entire group was 48% (Kaplan-Meier survival estimate, 95% confidence interval). The estimated 5-year survival for stage III was 33%, and for stage IV was 30%. There were no deaths in patients with stage II group. The estimated 5-year survival for the treated group (8 patients) was 33% and 58% for the untreated group (10 patients). Conclusions: In PACs, surgery remains the main method of therapy. In our experience, Mitotane with or without chemotherapy did not improve survival. No significant financial relationships to disclose." @default.
• W2966072279 created "2019-08-13" @default.
• W2966072279 creator A5065201740 @default.
• W2966072279 creator A5068920217 @default.
• W2966072279 date "2006-06-20" @default.
• W2966072279 modified "2023-09-25" @default.
• W2966072279 title "Primary adrenocortical carcinoma: A retrospective review of The Cleveland Clinic Foundation experience between 1995 to 2002" @default.
• W2966072279 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.18614" @default.
• W2966072279 hasPublicationYear "2006" @default.
• W2966072279 type Work @default.
• W2966072279 sameAs 2966072279 @default.
• W2966072279 citedByCount "0" @default.
• W2966072279 crossrefType "journal-article" @default.
• W2966072279 hasAuthorship W2966072279A5065201740 @default.
• W2966072279 hasAuthorship W2966072279A5068920217 @default.
• W2966072279 hasConcept C120665830 @default.
• W2966072279 hasConcept C121332964 @default.
• W2966072279 hasConcept C126322002 @default.
• W2966072279 hasConcept C141071460 @default.
• W2966072279 hasConcept C146357865 @default.
• W2966072279 hasConcept C151730666 @default.
• W2966072279 hasConcept C167135981 @default.
• W2966072279 hasConcept C2776735609 @default.
• W2966072279 hasConcept C2777546739 @default.
• W2966072279 hasConcept C2780694816 @default.
• W2966072279 hasConcept C2781399356 @default.
• W2966072279 hasConcept C61511704 @default.
• W2966072279 hasConcept C71924100 @default.
• W2966072279 hasConcept C86803240 @default.
• W2966072279 hasConceptScore W2966072279C120665830 @default.
• W2966072279 hasConceptScore W2966072279C121332964 @default.
• W2966072279 hasConceptScore W2966072279C126322002 @default.
• W2966072279 hasConceptScore W2966072279C141071460 @default.
• W2966072279 hasConceptScore W2966072279C146357865 @default.
• W2966072279 hasConceptScore W2966072279C151730666 @default.
• W2966072279 hasConceptScore W2966072279C167135981 @default.
• W2966072279 hasConceptScore W2966072279C2776735609 @default.
• W2966072279 hasConceptScore W2966072279C2777546739 @default.
• W2966072279 hasConceptScore W2966072279C2780694816 @default.
• W2966072279 hasConceptScore W2966072279C2781399356 @default.
• W2966072279 hasConceptScore W2966072279C61511704 @default.
• W2966072279 hasConceptScore W2966072279C71924100 @default.
• W2966072279 hasConceptScore W2966072279C86803240 @default.
• W2966072279 hasLocation W29660722791 @default.
• W2966072279 hasOpenAccess W2966072279 @default.
• W2966072279 hasPrimaryLocation W29660722791 @default.
• W2966072279 hasRelatedWork W2012572784 @default.
• W2966072279 hasRelatedWork W2063033516 @default.
• W2966072279 hasRelatedWork W2333126026 @default.
• W2966072279 hasRelatedWork W2423207660 @default.
• W2966072279 hasRelatedWork W2802888094 @default.
• W2966072279 hasRelatedWork W3093768612 @default.
• W2966072279 hasRelatedWork W35534053 @default.
• W2966072279 hasRelatedWork W4250125671 @default.
• W2966072279 hasRelatedWork W4317399159 @default.
• W2966072279 hasRelatedWork W4380870709 @default.
• W2966072279 isParatext "false" @default.
• W2966072279 isRetracted "false" @default.
• W2966072279 magId "2966072279" @default.
• W2966072279 workType "article" @default.